| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C1qC |
| Uniprot No | P02747 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-245aa |
| 氨基酸序列 | MDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGY DGLPGPKGEPGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPG PMGIPGEPGEEGRYKQKFQSVFTVTRQTHQPPAPNSLIRFNAVLTNPQGD YDTSTGKFTCKVPGLYYFVYHASHTANLCVLLYRSGVKVVTFCGHTSKTN QVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGFLLFPD |
| 预测分子量 | 52 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是与C1q重组蛋白相关的3篇文献概览(文献标题及作者为虚构示例，仅作参考)：
1. **《Functional characterization of recombinant human C1qC subunit in complement activation》**
- **作者**：Smith A, et al.
- **摘要**：研究利用昆虫细胞表达系统成功重组人C1qC蛋白，证实其与C1qA/B亚基组装形成功能性C1复合物，并通过体外实验验证其介导补体经典途径激活的能力。
2. **《Expression and purification of the C1qC domain in E. coli for structural studies》**
- **作者**：Li X, et al.
- **摘要**：报道通过大肠杆菌原核表达系统高效制备重组C1qC蛋白，优化纯化方法后获得高纯度蛋白，并利用X射线晶体学解析其三维结构，揭示其与免疫复合物结合的分子机制。
3. **《Recombinant C1qC modulates immune response in autoimmune disease models》**
- **作者**：Garcia R, et al.
- **摘要**：探讨重组C1qC蛋白在类风湿性关节炎小鼠模型中的作用，发现其通过调节补体通路抑制炎症反应，为靶向C1q的免疫治疗提供潜在策略。
(注：以上文献信息为模拟生成，实际研究需查阅PubMed、Web of Science等平台获取真实数据。)
C1qC recombinant protein is a biologically engineered component derived from the C1q complex, a critical element of the innate immune system. C1q, part of the C1 complex in the complement system, plays a central role in recognizing pathogens, immune complexes, and apoptotic cells. Structurally, C1q comprises six heterotrimeric subunits, each containing three distinct chains (C1qA, C1qB, and C1qC). The C1qC chain is essential for forming the collagen-like region of C1q, enabling interactions with immunoglobulins (IgG/IgM) and initiating the classical complement pathway.
Recombinant C1qC is produced using expression systems like *E. coli* or mammalian cells, allowing precise control over protein purity and function. Its production addresses challenges in studying native C1q, which is difficult to isolate due to low abundance and structural complexity. Researchers use recombinant C1qC to investigate immune activation mechanisms, particularly how C1q binds to antigens or immune complexes to trigger downstream complement cascades. It also aids in exploring autoimmune diseases (e.g., lupus) linked to aberrant complement activity, as C1q deficiencies or dysfunction correlate with impaired immune tolerance.
Additionally, recombinant C1qC serves as a tool for structural studies, drug screening, and therapeutic development. For example, it helps design inhibitors targeting complement overactivation or engineer chimeric proteins for targeted immunotherapy. By enabling scalable, reproducible production, this recombinant protein enhances our understanding of complement biology and its translational applications in immunology and medicine.
×
